Journal of Gastrointestinal Cancer最新文献

{"title":"Outcomes of Neoadjuvant Chemoradiotherapy Using Volumetric Modulated Arc Therapy in Locally Advanced Squamous Cell Oesophageal Cancers.","authors":"Sam David, Naveen Mummudi, Anil Tibdewal, Sabita Jiwnani, Karthik V, Kumar Prabhash, Trupti Pai, Jai Prakash Agarwal","doi":"10.1007/s12029-025-01225-9","DOIUrl":"10.1007/s12029-025-01225-9","url":null,"abstract":"<p><strong>Purpose: </strong>Neoadjuvant chemoradiotherapy has been established as the standard of care for locally advanced oesophageal cancers. Most of the evidences on neoadjuvant chemoradiotherapy (NACTRT) comes from the Western world where the predominant histology is adenocarcinoma. This study aimed to study the outcomes of neoadjuvant chemoradiotherapy using CROSS protocol and volumetric modulated arc therapy (VMAT) in locally advanced squamous cell oesophageal cancers.</p><p><strong>Case presentation: </strong>We report a multicentric abdominal inflammatory myofibroblastic tumor in a 6-year-old girl who presented with massive abdominal distention. The sheer size of the mass, coupled with multicentric presentation and absent mobility on clinical examination, would have led to a very morbid surgical exploration. This patient was treated with initial chemotherapy, which led to a dramatic response in both symptoms and size of masses, facilitating a complete surgical resection with negligible postoperative morbidity.</p><p><strong>Methods: </strong>This was a single-institute retrospective analysis utilizing a prospectively collected database where all patients with locally advanced operable oesophageal cancers with squamous histology diagnosed between 2021 and 2022 were screened and included. All patients received neoadjuvant chemoradiotherapy in accordance with the CROSS protocol with all patients receiving radiotherapy using VMAT technique.</p><p><strong>Results: </strong>A total of 102 patients with locally advanced oesophageal cancers with squamous histology were included in the study. The median follow-up for the cohort was 29 months. The 3-year overall survival (OS), disease-free survival (DFS), and local control (LC) were 72%, 59.1%, and 72%, respectively. Pathological complete response was 59.4%. The major Clavien-Dindo classification (≥ class 3) of surgical complications was 32%. Lower incidence of pulmonary (17.7%) and cardiac (5.2%) complications was observed in this cohort.</p><p><strong>Conclusions: </strong>NACTRT using the CROSS protocol enhances the pathological complete response rates and the survival outcomes in locally advanced oesophageal cancers with squamous histology. The utilization of VMAT has been associated with a reduction in postoperative cardiopulmonary toxicities. However, further prospective randomised studies are required to validate the technique's superiority.</p>","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"56 1","pages":"118"},"PeriodicalIF":1.6,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12075281/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144012536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Concurrent Coprimary KIT Exon 17 and BRAF Mutations in a Small Intestinal GI Stromal Tumor-A Case Report.","authors":"Hashim Ishfaq, Misbah Younus Soomro, Bakhtawar Masood, Rashida Ahmed, Yasmin Abdul Rashid","doi":"10.1007/s12029-025-01236-6","DOIUrl":"https://doi.org/10.1007/s12029-025-01236-6","url":null,"abstract":"<p><strong>Purpose: </strong>Gastrointestinal stromal tumors (GISTs) are rare neoplasms driven by mutations in KIT, PDGFRA, or BRAF. Concomitant KIT/BRAF mutations are exceptionally rare and have historically been regarded as mutually exclusive. We report the first documented instance of a GIST with concurrent KIT exon 17 (D816H) and BRAF exon 15 (V600E) mutations, exploring the implications of these mutations for treatment and prognosis. KIT exon 17 mutations are rare and associated with imatinib resistance, and the literature on concurrent KIT/PDGFRA and BRAF mutations is limited, highlighting the potential of this case to provide valuable insights into the management of similar tumors.</p><p><strong>Methods: </strong>A 70-year-old woman presented with abdominal pain and a 20-year history of intermittent melena. Imaging and histopathological examination confirmed a duodenal GIST. The patient underwent en bloc tumor resection, and next-generation sequencing (NGS) identified co-occurring KIT exon 17 (D816H) and BRAF exon 15 (V600E) mutations. Postoperatively, the patient received adjuvant imatinib therapy for a planned duration of 3 years.</p><p><strong>Results: </strong>The patient tolerated adjuvant imatinib therapy well, experiencing only mild nausea and diarrhea. After 2 years of follow-up, no recurrence of the tumor was detected, and the patient remained in radiological remission with no signs of metastasis or tumor progression.</p><p><strong>Conclusion: </strong>This case demonstrates a favorable outcome in a patient with localized GIST with concomitant KIT exon 17 and BRAF mutations following surgical resection with no evidence of recurrence. These findings underscore the significance of early comprehensive genotyping in GISTs to guide therapy and predict imatinib resistance.</p>","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"56 1","pages":"116"},"PeriodicalIF":1.6,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144022354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Personalized Care for Pancreatic Cancer: Harnessing Patient-Derived Organoids.","authors":"L Demyan, M J Weiss","doi":"10.1007/s12029-025-01164-5","DOIUrl":"https://doi.org/10.1007/s12029-025-01164-5","url":null,"abstract":"<p><p>Pancreatic ductal adenocarcinoma (PDAC) is one of the most fatal cancers. Surgical resection combined with appropriate chemotherapy currently offers the best chance for long-term survival and potential cure. However, effective treatment is hindered by the limited chemotherapy options and the absence of reliable clinical tools to guide chemotherapy selection. Patient-derived organoids (PDOs) have emerged as a promising technology with the potential in precision medicine for PDAC. This review provides an overview of pancreatic organoid genesis, explores the role of PDOs in elucidating PDAC biology within clinically relevant contexts, and concludes by examining current literature on the utility of PDOs as biomarkers for personalized treatment strategies.</p>","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"56 1","pages":"113"},"PeriodicalIF":1.6,"publicationDate":"2025-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143969603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Significance of Screening Endoscopy at 2-Year Interval for Detecting Pharyngeal and Esophageal Cancer in the Japanese General Population.","authors":"Kazuhiro Kashiwagi, Toshifumi Yoshida, Satoshi Kinoshita, Hiromasa Nakamizo, Rieko Nakamura, Hiromasa Takaishi, Yasushi Iwao, Takanori Kanai","doi":"10.1007/s12029-025-01243-7","DOIUrl":"10.1007/s12029-025-01243-7","url":null,"abstract":"<p><strong>Purpose: </strong>We previously identified examination time and 2-year interval as effective quality indicators for detecting upper gastrointestinal cancer during screening esophagogastroduodenoscopy (EGD). We evaluated the significance of biennial endoscopy in detecting pharyngeal and esophageal cancer.</p><p><strong>Methods: </strong>Individuals who underwent multiple EGD examinations as health checkups at our center between August 2012 and January 2022 were included. Endoscopists were categorized into two groups based on their mean examination time for normal EGD findings, using a threshold of 5 min. The associations between cancer detection rate and these indicators were analyzed using multivariable analyses.</p><p><strong>Results: </strong>Twelve endoscopists performed more than 1000 examinations each, for a total of 28,842 examinations, detecting all (6 pharyngeal and 26 esophageal) cancers. Intervals between endoscopies were classified into three groups: ≤ 1 year (Group 1), 1 to ≤ 2 years (Group 2), and > 2 years (Group 3). This cancer detection rate did not differ significantly between Groups 1 and 2 (p = 0.761) but was significantly higher in Group 3 than in Group 2 (OR = 4.356, 95% CI = 1.161-16.333, p = 0.029). When Groups 1 and 2 were combined (≤ 2 years) and compared with Group 3, an interval of > 2 years was significantly associated with a higher detection rate, including cases not curable by endoscopic resection (OR, 4.710; 95% CI, 1.806-12.282; p = 0.002). Examination time was not associated with the cancer detection rate (p = 0.944).</p><p><strong>Conclusions: </strong>These findings support the significance of biennial endoscopy in detecting pharyngeal and esophageal cancer as well.</p>","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"56 1","pages":"114"},"PeriodicalIF":1.6,"publicationDate":"2025-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144007383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Fecal Immunochemical Testing for Colorectal Cancer Prevention in Two Public Hospitals.","authors":"Changlin Gong, Maria Teresa Medina Rojas, Maria Gabriela Rubianes Guerrero, Michail Kladas, Arameh Mousakhanian, Aarushi Sudan, Adejoke Johnson, Kimberly Cartmill, Elana Sydney, Donald P Kotler","doi":"10.1007/s12029-025-01223-x","DOIUrl":"https://doi.org/10.1007/s12029-025-01223-x","url":null,"abstract":"","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"56 1","pages":"115"},"PeriodicalIF":1.6,"publicationDate":"2025-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12065720/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143967831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neoadjuvant Pembrolizumab Enables Successful Downstaging and Resection of Borderline Resectable MSI-H/dMMR Pancreatic Ductal Adenocarcinoma: A Case Report and Literature Review.","authors":"Kevin Zhao, Vijayaragavan Muralidharan, Shaun Brown, Anthony Upton, Moammar Alshimirti, Prasad D Cooray","doi":"10.1007/s12029-025-01237-5","DOIUrl":"https://doi.org/10.1007/s12029-025-01237-5","url":null,"abstract":"<p><strong>Background: </strong>Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy with a poor prognosis. While immunotherapy has shown limited efficacy in most PDAC cases due to an immunosuppressive tumour microenvironment, tumours with microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) status exhibit increased responsiveness to immune checkpoint inhibitors.</p><p><strong>Case presentation: </strong>We report the case of a 45-year-old woman with Lynch syndrome who was diagnosed with MSI-H/dMMR PDAC during routine surveillance. Given the borderline resectable nature of her tumour and previous chemotherapy-related neurotoxicity, she was treated with neoadjuvant pembrolizumab instead of conventional chemotherapy. Following four cycles of pembrolizumab, imaging revealed a marked metabolic response, allowing for successful R0 pancreatoduodenectomy. Postoperative histology confirmed a significant reduction in tumour size, and immunohistochemical analysis demonstrated increased CD8 + T cell infiltration, supporting an enhanced anti-tumour immune response. The patient continues adjuvant pembrolizumab therapy without complications.</p><p><strong>Conclusion: </strong>This case highlights the potential role of neoadjuvant pembrolizumab in MSI-H/dMMR PDAC, demonstrating successful tumour downstaging and facilitating surgical resection. Our findings support further investigation into the integration of immunotherapy as a neoadjuvant strategy for select PDAC patients.</p>","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"56 1","pages":"112"},"PeriodicalIF":1.6,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12062155/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143997206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Association Between Health Literacy and Colorectal Cancer Screening: Findings Using a Three-Question Health Literacy Measure.","authors":"Alfonsus Adrian H Harsono, Rachel Ruiz, Meghna Katta, Hannah Ficarino Sheffer, Marshall Chandler McLeod, Smita Bhatia, Terry Davis, Daniel I Chu, Robert H Hollis","doi":"10.1007/s12029-025-01241-9","DOIUrl":"10.1007/s12029-025-01241-9","url":null,"abstract":"<p><strong>Purpose: </strong>Health literacy (HL) can impact health behaviors including colorectal cancer (CRC) screening. Prior findings using extensive measures of HL suggested that low HL is associated with lower CRC screening rates. We hypothesized that low HL, when measured using a clinically applicable three-question measure, would also be associated with low CRC screening rates.</p><p><strong>Methods: </strong>Data collected from the 2016 Behavioral Risk Factor Surveillance System (BRFSS) was utilized from 17 states that included a three-question HL measure. Participants ages 50-75 were included. The HL scores were categorized as adequate, marginal, or limited HL. The primary outcome was United States Preventative Services Task Force (USPSTF) recommendation-concordant CRC screening. The relationship between HL and CRC screening was examined using multivariable logistic regression.</p><p><strong>Results: </strong>Among 38,044 participants who met inclusion criteria, 47.2% (n = 17,950), 49.9% (n = 18,989), and 2.9% (n = 1105) had adequate, marginal, and limited HL, respectively. Lower HL levels were associated with lower adherence to USPSTF CRC screening recommendations: 73.3% for adequate, 68.0% for marginal, and 48.9% for limited HL (p < 0.01). Respondents with limited HL were 45% less likely to undergo CRC screening (OR = 0.55; 95%CI: 0.48-0.63). A significant interaction (p < 0.01) between health literacy and sex was identified. CRC screening difference among HL levels was more pronounced for male (OR = 0.48; 95% CI: 0.40-0.79) than female respondents (OR = 0.63; 95% CI: 0.52-0.76).</p><p><strong>Conclusion: </strong>Limited health literacy is associated with significantly lower rates of appropriate CRC screening, particularly for males. This three-question HL measure provides a clinically applicable tool to identify people at risk for lack of CRC screening.</p>","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"56 1","pages":"111"},"PeriodicalIF":1.6,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144007487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Submucosal Tunneling Endoscopic Resection for Upper Gastrointestinal Subepithelial Lesions: A Systematic Review and Meta-Analysis.","authors":"Stavros Chrysovalantis Liapis, Ioannis Baloyiannis, Konstantinos Perivoliotis, Dimitrios Lytras, George Tzovaras","doi":"10.1007/s12029-025-01235-7","DOIUrl":"10.1007/s12029-025-01235-7","url":null,"abstract":"<p><strong>Aim: </strong>Submucosal tunneling endoscopic resection (STER) is an advanced endoscopic technique used for the minimally invasive removal of subepithelial lesions of the gastrointestinal (GI) tract. The aim of this study was to evaluate the safety and efficacy of STER for upper gastrointestinal subepithelial lesions.</p><p><strong>Methods: </strong>A comprehensive search of major scholar databases (until December 15, 2023) was performed. Complete resection rate was considered the primary outcome. En bloc resection, operation duration, length of stay (LOS), local recurrence, and periprocedural complications were considered secondary outcomes. Random-effects (RE) and fixed-effects (FE) models were used to generate the outcome estimates.</p><p><strong>Results: </strong>A total of 37 studies and 3795 patients were included. Pooled proportion of complete resection was 99% (95% CI 98.4-99.6%, p < 0.001). En bloc resection was achieved at 87.7% of cases. Overall mean operation duration was 64.2 min, while mean LOS was estimated at 4.93 days. The local recurrence rate was 0.1%. The two most common complications associated with STER were subcutaneous emphysema (5.5%) and pneumothorax (3%).</p><p><strong>Conclusion: </strong>STER is a highly feasible and safe treatment modality for upper GI subepithelial lesions.</p>","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"56 1","pages":"110"},"PeriodicalIF":1.6,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143969924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multidisciplinary Management of Anorectal Melanoma: a Retrospective Analysis of Surgical and Systemic Therapies from the National Cancer Database.","authors":"Richard Sassun, Annaclara Sileo, Jyi Cheng Ng, Davide Ferrari, Matthew S Block, William R G Perry, Nicholas P McKenna, Kristen K Rumer, David W Larson","doi":"10.1007/s12029-025-01234-8","DOIUrl":"https://doi.org/10.1007/s12029-025-01234-8","url":null,"abstract":"<p><strong>Purpose: </strong>Anorectal melanoma (ARM) represents a problematic scenario due to a 5-year overall survival (OS) rate below 20% and its increasing incidence. Due to its comparable OS, local surgery (LS) has replaced radical surgery (RS). Adjuvant chemotherapy (Adj-CHT) and adjuvant immunotherapy (Adj-IT) are common treatments for ARM, while neoadjuvant immunotherapy (Neo-IT) has not been investigated yet. This study aimed to determine the best treatment to improve the OS.</p><p><strong>Methods: </strong>Patients with non-metastatic ARM in the National Cancer 1Database (2011-2021) who underwent surgery and received Neo-IT, Adj-IT, or Adj-CHT were included. Two cohorts were created based on the surgical approach (LS or RS). In their respective cohorts, patients receiving Neo-IT, Adj-IT, or Adj-CHT were matched 1:1:1 based on age, tumor size and location, lymphovascular invasion, and nodal disease. Kaplan-Meier analyses compared the different groups' influence on the 3-year OS.</p><p><strong>Results: </strong>Sixty patients were included in the LS cohort. Among them, there was no difference in the 3-year OS at the Kaplan-Meier analysis (Neo-IT 61%, Adj-IT 47.1%, and Adj-CHT 44%). Thirty-six patients were included in the RS cohort. Kaplan-Meier analysis for this group revealed that Neo-IT was a protective factor for 3-year OS (Neo-IT 71%, Adj-IT 11%, Adj-CHT 8%; p-value = 0.002).</p><p><strong>Conclusion: </strong>Neo-IT + RS seems to improve the 3-year OS compared to the other common treatments for ARM. Neo-IT + RS can be considered a valuable treatment since prospective trials are challenging for rare diseases. When RS is not feasible, Neo-IT + LS may be beneficial as the 3-year OS reaches 61%.</p>","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"56 1","pages":"108"},"PeriodicalIF":1.6,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144015196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Efficacy and Safety of Nivolumab Combined with Nab-Paclitaxel or Oxaliplatin as a First-Line Treatment for Advanced or Metastatic Gastric Cancer and Gastroesophageal Junction Cancer.","authors":"Juan Li, Shuman Li, Ying Zhang, Sisi Ye, Rongrui Liu, Weiwei Shi","doi":"10.1007/s12029-025-01211-1","DOIUrl":"https://doi.org/10.1007/s12029-025-01211-1","url":null,"abstract":"<p><strong>Objective: </strong>This study aims to assess the therapeutic efficacy and safety of nivolumab combined with chemotherapy as a first-line treatment for advanced or metastatic gastric cancer, specifically comparing the outcomes of oxaliplatin-based versus albumin-bound paclitaxel (nab-paclitaxel)-based therapies.</p><p><strong>Methods: </strong>We retrospectively analyzed 93 patients with advanced gastric cancer or gastroesophageal junction adenocarcinoma treated at the First Medical Center of Chinese PLA General Hospital from September 2017 to November 2022. Patients were categorized into the nivolumab + oxaliplatin (N-OX group) or nivolumab + nab-paclitaxel (N-AP group) based on the chemotherapy regimen. Progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and safety were evaluated as endpoints.</p><p><strong>Results: </strong>At the end of the follow-up period on September 31, 2023, we reported an ORR of 65.6% and DCR of 95.7% across all patients. The median PFS was 8.4 months, with no significant difference between the N-OX and N-AP groups (median, 7.8 vs 9.5 months; P = 0.450). Notably, patients with diffuse gastric cancer in N-AP group showed a 44.7% reduction in tumor progression risk compared with the N-OX group (P = 0.046). The overall safety profile was acceptable in two groups.</p><p><strong>Conclusions: </strong>Our study suggested that nivolumab combined with chemotherapy was effective and safe as a first-line intervention for advanced gastric cancer. While both oxaliplatin and nab-paclitaxel regimens showed similar efficacy, the nab-paclitaxel may offer additional benefits for patients with diffuse gastric cancer. Further research is encouraged to confirm these findings and refine treatment strategies.</p>","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"56 1","pages":"109"},"PeriodicalIF":1.6,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12037671/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144029447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}